Literature DB >> 29784587

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Marco Ruella1, Carl H June2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784587      PMCID: PMC5986966          DOI: 10.1016/j.ymthe.2018.05.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  26 in total

1.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 2.  Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Authors:  Marco Ruella; Carl H June
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

3.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Authors:  M Ruella; S S Kenderian; O Shestova; M Klichinsky; J J Melenhorst; M A Wasik; S F Lacey; C H June; S Gill
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

4.  Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

5.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Authors:  Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Juliane Gust; W Conrad Liles; Mark M Wurfel; José A López; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

6.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Authors:  James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

7.  Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development.

Authors:  L J Zhou; H M Smith; T J Waldschmidt; R Schwarting; J Daley; T F Tedder
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

8.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

9.  Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

Authors:  Biliang Hu; Jiangtao Ren; Yanping Luo; Brian Keith; Regina M Young; John Scholler; Yangbing Zhao; Carl H June
Journal:  Cell Rep       Date:  2017-09-26       Impact factor: 9.423

10.  CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Christopher C Kloss; Gertrude Gunset; Michel Sadelain
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more
  5 in total

Review 1.  Emerging Cellular Therapies for Cancer.

Authors:  Sonia Guedan; Marco Ruella; Carl H June
Journal:  Annu Rev Immunol       Date:  2018-12-10       Impact factor: 28.527

2.  Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.

Authors:  Kevin R Parker; Denis Migliorini; Eric Perkey; Kathryn E Yost; Aparna Bhaduri; Puneet Bagga; Mohammad Haris; Neil E Wilson; Fang Liu; Khatuna Gabunia; John Scholler; Thomas J Montine; Vijay G Bhoj; Ravinder Reddy; Suyash Mohan; Ivan Maillard; Arnold R Kriegstein; Carl H June; Howard Y Chang; Avery D Posey; Ansuman T Satpathy
Journal:  Cell       Date:  2020-09-21       Impact factor: 41.582

3.  Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.

Authors:  John P Murad; Dileshni Tilakawardane; Anthony K Park; Lupita S Lopez; Cari A Young; Jackson Gibson; Yukiko Yamaguchi; Hee Jun Lee; Kelly T Kennewick; Brenna J Gittins; Wen-Chung Chang; Chau P Tran; Catalina Martinez; Anna M Wu; Robert E Reiter; Tanya B Dorff; Stephen J Forman; Saul J Priceman
Journal:  Mol Ther       Date:  2021-02-27       Impact factor: 12.910

Review 4.  Immune Cells and Immunotherapy for Cardiac Injury and Repair.

Authors:  Joel G Rurik; Haig Aghajanian; Jonathan A Epstein
Journal:  Circ Res       Date:  2021-05-27       Impact factor: 23.213

Review 5.  The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.

Authors:  Dongfang Liu; Saiaditya Badeti; Gianpietro Dotti; Jie-Gen Jiang; He Wang; James Dermody; Patricia Soteropoulos; Deanna Streck; Raymond B Birge; Chen Liu
Journal:  Cell Commun Signal       Date:  2020-08-25       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.